Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013–July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/18/4639 |
| _version_ | 1797519992944590848 |
|---|---|
| author | Monique K. van der Kooij Olaf M. Dekkers Maureen J. B. Aarts Franchette W. P. J. van den Berkmortel Marye J. Boers-Sonderen Jan Willem B. de Groot Geke A. P. Hospers Djura Piersma Rozemarijn S. van Rijn Karijn P. M. Suijkerbuijk Hans M. Westgeest Astrid A. M. van der Veldt Gerard Vreugdenhil Sofie Wilgenhof Michel W. J. M. Wouters John B. A. G. Haanen Alfonsus J. M. van den Eertwegh Ellen Kapiteijn |
| author_facet | Monique K. van der Kooij Olaf M. Dekkers Maureen J. B. Aarts Franchette W. P. J. van den Berkmortel Marye J. Boers-Sonderen Jan Willem B. de Groot Geke A. P. Hospers Djura Piersma Rozemarijn S. van Rijn Karijn P. M. Suijkerbuijk Hans M. Westgeest Astrid A. M. van der Veldt Gerard Vreugdenhil Sofie Wilgenhof Michel W. J. M. Wouters John B. A. G. Haanen Alfonsus J. M. van den Eertwegh Ellen Kapiteijn |
| author_sort | Monique K. van der Kooij |
| collection | DOAJ |
| description | Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013–July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3–4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference. |
| first_indexed | 2024-03-10T07:50:34Z |
| format | Article |
| id | doaj.art-ac0de538cce042d19dfd6acb34ba763d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T07:50:34Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ac0de538cce042d19dfd6acb34ba763d2023-11-22T12:18:17ZengMDPI AGCancers2072-66942021-09-011318463910.3390/cancers13184639Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort StudyMonique K. van der Kooij0Olaf M. Dekkers1Maureen J. B. Aarts2Franchette W. P. J. van den Berkmortel3Marye J. Boers-Sonderen4Jan Willem B. de Groot5Geke A. P. Hospers6Djura Piersma7Rozemarijn S. van Rijn8Karijn P. M. Suijkerbuijk9Hans M. Westgeest10Astrid A. M. van der Veldt11Gerard Vreugdenhil12Sofie Wilgenhof13Michel W. J. M. Wouters14John B. A. G. Haanen15Alfonsus J. M. van den Eertwegh16Ellen Kapiteijn17Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The NetherlandsDepartment of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ Maastricht, The NetherlandsDepartment of Medical Oncology, Zuyderland Medical Center, 6130 MB Sittard-Geleen, The NetherlandsDepartment of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The NetherlandsIsala Oncology Center, Isala, 8000 GK Zwolle, The NetherlandsDepartment of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The NetherlandsDepartment of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The NetherlandsDepartment of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The NetherlandsDepartment of Internal Medicine, Amphia Ziekenhuis, Molengracht 21, 4818 CK Breda, The NetherlandsDepartments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA Rotterdam, The NetherlandsDepartment of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB Veldhoven, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ Amsterdam, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The NetherlandsRecent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013–July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3–4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.https://www.mdpi.com/2072-6694/13/18/4639sexadvanced melanomaimmunotherapytargeted therapyprospective nation-wide data |
| spellingShingle | Monique K. van der Kooij Olaf M. Dekkers Maureen J. B. Aarts Franchette W. P. J. van den Berkmortel Marye J. Boers-Sonderen Jan Willem B. de Groot Geke A. P. Hospers Djura Piersma Rozemarijn S. van Rijn Karijn P. M. Suijkerbuijk Hans M. Westgeest Astrid A. M. van der Veldt Gerard Vreugdenhil Sofie Wilgenhof Michel W. J. M. Wouters John B. A. G. Haanen Alfonsus J. M. van den Eertwegh Ellen Kapiteijn Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study Cancers sex advanced melanoma immunotherapy targeted therapy prospective nation-wide data |
| title | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study |
| title_full | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study |
| title_fullStr | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study |
| title_full_unstemmed | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study |
| title_short | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study |
| title_sort | sex based differences in treatment with immune checkpoint inhibition and targeted therapy for advanced melanoma a nationwide cohort study |
| topic | sex advanced melanoma immunotherapy targeted therapy prospective nation-wide data |
| url | https://www.mdpi.com/2072-6694/13/18/4639 |
| work_keys_str_mv | AT moniquekvanderkooij sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT olafmdekkers sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT maureenjbaarts sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT franchettewpjvandenberkmortel sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT maryejboerssonderen sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT janwillembdegroot sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT gekeaphospers sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT djurapiersma sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT rozemarijnsvanrijn sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT karijnpmsuijkerbuijk sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT hansmwestgeest sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT astridamvanderveldt sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT gerardvreugdenhil sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT sofiewilgenhof sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT michelwjmwouters sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT johnbaghaanen sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT alfonsusjmvandeneertwegh sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy AT ellenkapiteijn sexbaseddifferencesintreatmentwithimmunecheckpointinhibitionandtargetedtherapyforadvancedmelanomaanationwidecohortstudy |